Compare · BSX vs KIDS
BSX vs KIDS
Side-by-side comparison of Boston Scientific Corporation (BSX) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $92.25B, about 221.8x KIDS ($415.9M).
- Both names hit the wire about 3 times in the past 4 weeks.
- BSX has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- Boston Scientific Corporation
- OrthoPediatrics Corp.
- Price
- $62.06-5.52%
- $16.16-0.28%
- Market cap
- $92.25B
- $415.9M
- 1M return
- -11.05%
- -
- 1Y return
- -39.23%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 3
- 3
- Recent ratings
- 25
- 8
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest KIDS
- SEC Form DEF 14A filed by OrthoPediatrics Corp.
- SEC Form DEFA14A filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
- OrthoPediatrics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
- COO and CFO Hite Fred was granted 77,405 shares and sold $224,129 worth of shares (12,993 units at $17.25), increasing direct ownership by 30% to 277,477 units (SEC Form 4)
- Pres. Trauma & Def. Correction Hauser Joseph W was granted 65,700 shares and sold $148,281 worth of shares (8,596 units at $17.25), increasing direct ownership by 41% to 194,767 units (SEC Form 4)
- President and CEO Bailey David R sold $336,979 worth of shares (19,535 units at $17.25), decreasing direct ownership by 6% to 298,020 units (SEC Form 4)
- President of Scoliosis Odle Gregory A sold $145,469 worth of shares (8,433 units at $17.25) and was granted 47,380 shares, increasing direct ownership by 26% to 187,735 units (SEC Form 4)
- General Counsel and Secretary Gerritzen Daniel J was granted 47,380 shares and sold $148,592 worth of shares (8,614 units at $17.25), increasing direct ownership by 35% to 149,533 units (SEC Form 4)